128940:KRXHanmi Pharm. Co., Ltd. Analysis
Data as of 2026-06-17 - not real-time
₩446,500.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Hanmi Pharm. is trading near its 200‑day moving average with a neutral RSI and a bearish MACD divergence, suggesting limited upside in the immediate term. Fundamentally, the company shows modest revenue growth, solid operating margins, and a low payout ratio that supports dividend sustainability, but a DCF valuation places the fair value far below the current market price, indicating potential overvaluation.
The recent licensing agreement with Eli Lilly for the sonefpeglutide analog adds a meaningful catalyst that could improve the growth narrative, while the stock’s high 30‑day volatility and decreasing volume signal heightened short‑term risk. Investors should weigh the strong pipeline and dividend safety against the valuation gap and market volatility when deciding on positioning.
The recent licensing agreement with Eli Lilly for the sonefpeglutide analog adds a meaningful catalyst that could improve the growth narrative, while the stock’s high 30‑day volatility and decreasing volume signal heightened short‑term risk. Investors should weigh the strong pipeline and dividend safety against the valuation gap and market volatility when deciding on positioning.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD histogram
- Neutral RSI indicating no strong momentum
- Decreasing volume trend raising liquidity concerns
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Licensing partnership with Eli Lilly expanding pipeline
- Stable dividend with low payout ratio
- Operating margins above industry average
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Long‑term growth potential in obesity, oncology and rare diseases
- Consistent cash flow generation supporting financial health
- Strategic presence across multiple geographies reducing single‑market dependence
Key Metrics & Analysis
Financial Health
Revenue Growth0.50%
Profit Margin11.13%
P/E Ratio26.5
ROE14.09%
ROA6.25%
Debt/Equity28.29
Op. Cash Flow₩205.4B
Free Cash Flow₩35.9B
Industry P/E24.3
Technical Analysis
TrendNeutral
RSI48.4
Support₩385,000.00
Resistance₩578,000.00
MA 20₩453,900.00
MA 50₩470,480.00
MA 200₩446,705.00
MACDBearish
VolumeDecreasing
Fear & Greed Index88.5
Valuation
Fair Value₩28,984.75
Target Price₩599,333.30
Upside/Downside34.23%
GradeOvervalued
TypeValue
Dividend Yield0.47%
Risk Assessment
Beta0.89
Volatility83.88%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.